Ying Zheng

In recent years, active monomers derived from Chinese herbal medicine and their derivatives have attracted significant attention in the field of skincare product development. Artemisinin and its derivatives, including dihydroartemisinin (DHA), exhibit diverse pharmacological activities such as anti-inflammatory, antibacterial, immunomodulatory, and antitumor effects, showing promising therapeutic potential in skin-related diseases. However, systematic studies on artemisinins in cosmetics are lacking. This study aimed to evaluate the cosmetic potential of DHA by investigating its anti-aging, anti-hair loss, antibacterial, whitening, and anti-glycation activities. Results showed that DHA exhibits multiple biological activities: DHA exhibits anti-aging activity by promoting collagen I synthesis in HDF cell, exhibits anti-hair loss effect by modulating VEGF and DKK1 expression in DPC cell, exhibits antibacterial activity against Malassezia furfur, exhibits whitening activity by suppressing melanin synthesis, and exhibits anti-glycation activity by suppressing glycation reactions. Overall, with the broad biological activities, we believe that DHA holds encouraging promise in the cosmetics industry.

Sonosensitizers play a crucial role in the efficacy of sonodynamic antitumor therapy (SDT) and sonodynamic antimicrobial chemotherapy (SACT), highlighting the necessity for the development of new compounds with good sonodynamic activity. In this study, three novel 3-substituted ciprofloxacin derivatives (CIPD1, CIPD2, and CIPD3) were designed and synthesized. Their sonodynamic activities were evaluated by assessing the damage to bovine serum albumin (BSA) and Escherichia coli (E. coli). Furthermore, the potential mechanism underlying their sonodynamic damage activities was investigated by detecting reactive oxygen species (ROS) under ultrasound irradiation (US). The results demonstrated that all three derivatives exhibited enhanced sonodynamic damage to BSA and E. coli under US, with CIPD1 and CIPD2 showing superior effectiveness compared to CIP. Both the concentrations of derivatives and the duration of ultrasound irradiation were found to significantly impact their sonodynamic effects. All three CIP derivates could be activated to produce ROS following ultrasound irradiation, primarily consisting of ¹O₂ and ·OH. The levels of ROS production were positively correlated with their sonodynamic activities, potentially explaining the mechanism underlying their sonodynamic damage activities.

LR004 is a novel chimeric (human/mouse) monoclonal antibody developed for the treatment of advanced colorectal carcinoma with detectable epidermal growth factor receptor (EGFR) expression. We aimed to investigate the preclinical pharmacokinetics (PK) and in vivo biodistribution of LR004. The PK profiles of LR004 were initially established in rhesus monkeys. Subsequently, ¹²⁵I radionuclide-labeled LR004 was developed and the biodistribution, autoradiography, and NanoSPECT/CT of ¹²⁵I-LR004 in xenograft mice bearing A431 tumors were examined. The PK data revealed a prolonged half-life and nonlinear PK characteristics of LR004 within the dose range of 6–54 mg/kg. The radiochemical purity of ¹²⁵I-LR004 was approximately 98.54%, and iodination of LR004 did not affect its specific binding activity to the EGFR antigen. In a classical biodistribution study, ¹²⁵I-LR004 exhibited higher uptake in highly perfused organs than in poorly perfused organs. Prolonged retention properties of ¹²⁵I-LR004 in tumors were observed at 4 and 10 days. Autoradiography and NanoSPECT/CT confirmed the sustained retention of ¹²⁵I-LR004 at the tumor site in xenograft mice. These findings demonstrated the adequate tumor targeting capabilities of ¹²⁵I-LR004 in EGFR-positive tumors, which may improve dosing strategies and future drug development.

LR004 is a novel chimeric (human/mouse) monoclonal antibody developed for the treatment of advanced colorectal carcinoma with detectable epidermal growth factor receptor (EGFR) expression. We aimed to investigate the preclinical pharmacokinetics (PK) and in vivo biodistribution of LR004. The PK profiles of LR004 were initially established in rhesus monkeys. Subsequently, 125I radionuclide-labeled LR004 was developed and its binding activity to the EGFR antigen were evaluated. Furthermore, the biodistribution, autoradiography, and NanoSPECT/CT of 125I-LR004 in xenograft mice bearing A431 tumors were examined. The PK data revealed a prolonged half-life and nonlinear PK characteristics of LR004 within the dose range of 6–54 mg/kg. The radiochemical purity of 125I-LR004 was approximately 98.54%, and iodination of LR004 did not affect its specific binding activity to the EGFR antigen. In a classical biodistribution study, 125I-LR004 exhibited higher uptake in highly perfused organs than in poorly perfused organs. Prolonged retention properties of 125I-LR004 in tumors were observed at 4 and 10 days. Autoradiography and NanoSPECT/CT confirmed the significant accumulation and sustained retention of 125I-LR004 at the tumor site in xenograft mice. These findings demonstrated the adequate tumor targeting capabilities of 125I-LR004 in EGFR-positive tumors, which may improve dosing strategies and future drug development.